Nihon Medi-Physics Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising a peptide-modified antibody targeting B-lymphocyte antigen CD20 covalently linked to a radionuclide-chelating agent through a linker reported to be useful for the diagnosis and treatment of cancer.
Emory University and Medical College of Wisconsin have presented quinazolinone derivatives acting as NADPH oxidase (NOX) inhibitors reported to be useful for the treatment of traumatic brain injury and epilepsy.
Merck Sharp & Dohme Corp. has disclosed plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema, diabetic macular edema, retinal vein occlusion, wet macular degeneration (exudative) and uveitis.
Investigators at the University of Copenhagen and affiliated organizations presented data from a study that aimed to validate differentially expressed genes (DEGs) in mesial temporal lobe epilepsy (mTLE) as potential new targets.
Pfizer Inc. and Biontech SE have initiated a phase I study to evaluate the safety, tolerability and immunogenicity of BNT-162b4, a next-generation COVID-19 vaccine candidate that aims to enhance SARS-CoV-2 T-cell responses and potentially broaden protection against COVID-19.
RSS
